Search results

Filter (6 in use)

Type 2 selected

  • Remove filter for Guidance (1)
  • Remove filter for NICE Pathways

Status 2 selected

  • Remove filter for Published (1)
  • Remove filter for Proposed

Last updated 1 selected

  • Remove filter for Last 3 months
  • Filter by Last 6 months
  • Filter by Last year
  • Filter by Last 3 years

Guidance programme 1 selected

  • Filter by NICE guidelines (18)
  • Filter by Technology appraisal guidance (18)
  • Filter by Clinical guidelines (11)
  • Filter by COVID-19 rapid guidelines (6)
  • Filter by Medical technologies guidance (3)
  • Filter by Interventional procedures guidance (2)
  • Remove filter for Highly specialised technologies guidance (1)
  • Filter by Social care guidelines (1)

1 result

Sorted by Date . | Sort by Relevance

  • Guidance Remove Guidance filter
  • NICE Pathways Remove NICE Pathways filter
  • Published Remove Published filter
  • Proposed Remove Proposed filter
  • Last 3 months Remove Last 3 months filter
  • Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
  1. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

    Type
    Highly specialised technologies guidance
    Published
    24 February 2021
    View recommendations for HST14
    Show all sections for HST14

    Sections for HST14

    1. Overview
    2. 1 Recommendations
    3. 2 The condition
    4. 3 The technology
    5. 4 Consideration of the evidence
    6. 5 Implementation
    7. 6 Evaluation committee members and NICE project team